Indoco Remedies Ltd
NSE:INDOCO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Indoco Remedies Ltd
Gross Profit
Indoco Remedies Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Indoco Remedies Ltd
NSE:INDOCO
|
Gross Profit
₹11B
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Gross Profit
₹228.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Gross Profit
₹188.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
8%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Gross Profit
₹454.3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
8%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Gross Profit
₹189.9B
|
CAGR 3-Years
26%
|
CAGR 5-Years
14%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Gross Profit
₹96.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
Indoco Remedies Ltd
Glance View
Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-01-07. The firm is an integrated, research-oriented pharma company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm's geographical segments include India and Outside India. The firm has nine domestic marketing divisions with a brand portfolio in various therapeutic segments, including Gastrointestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management and Gyneacology. The Company’s brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cal-Aid, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM and Methycal.
See Also
What is Indoco Remedies Ltd's Gross Profit?
Gross Profit
11B
INR
Based on the financial report for Mar 31, 2025, Indoco Remedies Ltd's Gross Profit amounts to 11B INR.
What is Indoco Remedies Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
8%
Over the last year, the Gross Profit growth was -7%. The average annual Gross Profit growth rates for Indoco Remedies Ltd have been 3% over the past three years , 9% over the past five years , and 8% over the past ten years .
